Anthony Zook Net Worth

The estimated Net Worth of Anthony P. Zook is at least $5.08 mil dollars as of 10 August 2024. Mr. Zook owns over 11,336 units of Biosig Technologies Inc stock worth over $5,079 and over the last 11 years he sold BSGM stock worth over $0. In addition, he makes $0 as Director at Biosig Technologies Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Zook BSGM stock SEC Form 4 insiders trading

Anthony has made over 1 trades of the Biosig Technologies Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 11,336 units of BSGM stock worth $5,079 on 10 August 2024.

The largest trade he's ever made was exercising 11,336 units of Biosig Technologies Inc stock on 10 August 2024 worth over $5,079. On average, Anthony trades about 1,889 units every 0 days since 2013. As of 10 August 2024 he still owns at least 11,336 units of Biosig Technologies Inc stock.

You can see the complete history of Mr. Zook stock trades at the bottom of the page.

Anthony Zook biography

Anthony P. Zook serves as Director of the Company. Mr. Zook brings to the Company a wealth of commercialization experience in the life science industry gained primarily through his career at AstraZeneca Plc [LON:AZN]. Mr. Zook held several executive positions at AstraZeneca, including Executive Vice President of Global Commercial Operations from 2010 to 2013, President and Chief Executive Officer of the North American division from 2007 to 2010 and President of Medimmune, the wholly-owned biologics division of AstraZeneca, from 2008 to 2010. Under Mr. Zook's leadership, AstraZeneca commercialized ten blockbuster brands, each over $1 billion in sales. Along with the CEO, CFO, and Head of R&D, Mr. Zook sat on the Portfolio Investment Board (PIB), which set and approved the overall strategy for Research and Development and allocated resources by therapeutic area. Mr. Zook served or continues to serve on several boards, including the boards of AltheRx, Inhibikase, Rib-X Pharmaceuticals, the National Pharmaceutical Council, PhRMA, the Pennsylvania Division of the American Cancer Society and his alma mater, Frostburg State University. Mr. Zook earned a B.S. degree from Frostburg State University and an A.A. degree in chemical engineering from Pennsylvania State University.

How old is Anthony Zook?

Anthony Zook is 56, he's been the Director of Biosig Technologies Inc since 2020. There are 8 older and 4 younger executives at Biosig Technologies Inc. The oldest executive at Biosig Technologies Inc is Dr. Budimir S. Drakulic Ph.D., 71, who is the Chief Scientist.

What's Anthony Zook's mailing address?

Anthony's mailing address filed with the SEC is 9490 NEOGENOMICS WAY, , FORT MYERS, FL, 33912.

Insiders trading at Biosig Technologies Inc

Over the last 9 years, insiders at Biosig Technologies Inc have traded over $1,778,587 worth of Biosig Technologies Inc stock and bought 1,345,515 units worth $2,296,289 . The most active insiders traders include Kenneth L Londoner, Asher Holzer, eJerome B Zeldis. On average, Biosig Technologies Inc executives and independent directors trade stock every 24 days with the average trade being worth of $11,433. The most recent stock trade was executed by Kenneth L Londoner on 13 June 2023, trading 15,600 units of BSGM stock currently worth $19,344.

What does Biosig Technologies Inc do?

biosig technologies, inc. (otcqb: bsgm) is a medical device company that is developing a proprietary technology platform designed to greatly improve the $3 billion electrophysiology (ep) marketplace. led by a proven management team and a veteran, independent board of directors, minneapolis-based biosig is preparing to commercialize its pure ep system.

Complete history of Mr. Zook stock trades at Neogenomics, VIVUS, eBiosig Technologies Inc

Biosig Technologies Inc executives and stock owners

Biosig Technologies Inc executives and other stock owners filed with the SEC include:

• Kenneth Londoner,
  Executive Chairman of the Board, Chief Executive Officer
• Steven Chaussy,
  Chief Financial Officer
• Kenneth L. Londoner M.B.A., MBA,
  Founder, CEO & Exec. Chairman
• Samuel Navarro,
  Independent Director
• Jeffrey O'Donnell,
  Lead Independent Director
• Martha Pease,
  Independent Director
• Andrew Filler,
  Independent Director
• David Weild,
  Independent Director
• Patrick Gallagher,
  Independent Director
• Donald Foley,
  Independent Director
• Anthony Zook,
  Director
• Manasi Patwardhan,
  Director of Strategic Planning
• Olivier Chaudoir,
  Senior Director of Marketing
• Julie Stephenson,
  Vice President - Clinical Affairs, Senior Director of Clinical Affairs
• Andrew Ballou,
  Vice President - Investor Relations
• John Kowalski,
  Vice President - Sales
• John Sieckhaus,
  Chief Operating Officer
• Gray Fleming,
  Chief Commercial Officer
• Steven Chaussy,
  Chief Financial Officer
• Natasha Drapeau,
  Exec. VP
• Brenda Castrodad,
  Director of HR
• Lora Mikolaitis,
  VP of Admin.
• Dr. Budimir S. Drakulic Ph.D.,
  Chief Scientist
• Steven Eric Abelman,
  Director
• Steve Chaussy,
  Chief Financial Officer
• Roy T Tanaka,
  Director
• Lora Mikolaitis,
  10% owner
• Seth H. Z. Fischer,
  Director
• Joseph Rafferty,
  Chief Commercialization Offcr
• Jerome B Zeldis,
  Director
• Asher Holzer,
  Director
• Gregory D Cash,
  President and CEO
• James L Klein,
  Director
• James J Barry,
  Director
• John Sieckhaus,
  Chief Operating Officer
• Gray Fleming,
  Chief Commercial Officer
• Steven J Buhaly,
  Chief Financial Officer
• Frederick Hrkac,
  Director
• Donald Browne,
  Director
• Christopher Allen Baer,
  Director